Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Flux Therapeutics General Information
Flux Therapeutics develops next-generation genetic medicines using a proprietary platform based on Targeted Ubiquitin Modulators. Their lead program targets PRPF8 for rare congenital disorders, currently in the discovery/preclinical stage. No clinical results have been published as of early 2025[1][3].
Contact Information
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Flux Therapeutics Funding
No funding data available
To view Flux Therapeutics's complete valuation and funding history, request access »